- Amplia Therapeutics has obtained data from an animal study demonstrating its FAK inhibitors lower fibrosis arising from the NASH.
- The positive data from the animal study is anticipated to support the future development and partnering programs of ATX.
- The Company also disclosed that both FAK inhibitors showed a significant reduction in Alpha-SMA and ER-TR7.
Amplia Therapeutics Limited (ASX:ATX), a healthcare firm developing new drugs for cancer and fibrosis, announced that data from a pre-clinical study demonstrated that its FAK inhibitors, AMP886 and AMP945, showed a reduction in fibrosis.
Following the release of animal study data, ATX shares rose steeply on the ASX and were trading at AU$0.250, up 8.695% at AEST 1:58 PM. The market capitalisation of the Company stood at AU$24.83 million.
Source: Copyright © 2021 Kalkine Media Pty Ltd
A few other healthcare players were trading in green during the afternoon session. These included Analytica Limited (ASX:ALT), up 25%, AnteoTech Ltd (ASX:ADO), up 13.114%, and Medibio Limited (ASX:MEB), up 6.25% (at AEST 1:40 PM).
Let us zoom lens and discuss the announcement of ATX in detail-
Amplia’s FAK inhibitors show a significant reduction in fibrosis
On 20 April 2021, Amplia Therapeutics updated the market that the Company has obtained data from a pre-clinical animal study demonstrating both of its proprietary FAK (focal adhesion kinase) inhibitors lessen fibrosis developing from non-alcoholic steatohepatitis (NASH). Moreover, AMP945 showed a statistically substantial reduction in liver fibrosis.
The data from the study highlight FAK’s significant role in the underlying pathophysiology of multiple fibrotic indications.
Notably, SMC Laboratories Inc tested both FAK inhibitors, AMP886 and AMP945, using their proprietary STAM™ mouse model for NASH. Furthermore, the Company also disclosed that the two FAK inhibitors showed a significant reduction in Alpha-SMA and ER-TR7.
Alpha-SMA and ER-TR7 are two key activators of liver fibrosis.
- ER-TR7 is a marker for fibroblasts which are the cells that reduce collagen in fibrotic tissue.
- Alpha-SMA is a marker for fibroblasts activation.
The data from the study further support the Company’s view that FAK has a significant role in the pathology of several fibrotic diseases. Amplia has now proven anti-fibrotic activity for its FAK inhibitors in animal models of lung fibrosis and NASH as well as in various in vitro studies.
Considering these positive data, Amplia anticipates conducting additional exploratory, non-clinical studies to assess FAK inhibitors’ use as potential therapies for liver fibrosis as well as other fibrotic indications.
Data from the animal studies are anticipated to support future development and partnering programs of the Company.
John Lambert, CEO of Amplia: